GLP-1 claims on natural health products are appearing more frequently as consumer interest in metabolic health and weight management continues to grow. If your company plans to launch an NHP that references GLP-1, appetite regulation, or blood sugar support, you need to know where Health Canada draws the line. Misjudging that boundary can cost you your NPN licence, delay your product launch, or trigger enforcement action.
The challenge is that the line between a permissible structure-function claim and a prohibited drug claim is not always obvious. Health Canada regulates natural health products under the Natural Health Products Regulations (NHPR), and the rules around therapeutic claims are strict.
Understanding what language is acceptable before you file your product licence application will save you significant time, money, and organizational pain. This post covers what to check before you write your claims.
Why GLP-1 Language Is Attracting Regulatory Scrutiny
GLP-1, or glucagon-like peptide-1, is a hormone involved in insulin secretion, appetite regulation, and blood glucose control. Pharmaceutical GLP-1 receptor agonists such as semaglutide have become widely known, and that public awareness has created commercial pressure on the NHP space. Canadian retailers and publishers already promote GLP-1 supplements for weight management and blood sugar support. That trend puts pressure on brands to use similar language.
In January 2026, Health Canada issued a public advisory on unauthorized GLP-1 products. It reported retailers selling them in stores and online. It also said it is monitoring the marketplace and taking action, including seizures and compliance or warning letters. However, the advisory covers drugs, not NHPs. Even so, it shows that Health Canada is paying attention to this product category. Brands should therefore treat GLP-1 wording with care.
What Health Canada Permits for NHP Claims
Health Canada approves NHP claims based on the product’s evidence, the applicable monograph (where one exists), and the language of the claim itself. Also, you cannot sell an NHP in Canada without a product licence. Health Canada then issues a natural product number (NPN), which shows the product is authorized for sale. Our guide explains what an NPN is and why it matters.
For products that affect appetite, blood sugar, or metabolic function, you can review the compendium of Health Canada monographs to identify wording for specific ingredients. Using monograph-supported language significantly reduces review times and lowers the risk of a rejection.
How to Check Whether a Claim Has Support
Start with monographs. They let applicants rely on established evidence for ingredients used under set conditions. So you do not have to build that evidence from scratch. Health Canada now keeps the monographs in the Natural Health Products Ingredients Database. Follow these steps before you write any GLP-1 related copy:
- Search for your medicinal ingredient in the database.
- Read the approved uses, doses, and conditions in its monograph.
- Compare each draft claim to that wording.
- Flag any claim that goes beyond what the monograph says.
A monograph applies only under the conditions it sets. So check your dose and your intended use against it. A monograph may also not cover a GLP-1 related use at all. Confirm coverage for your exact ingredient and your exact wording.
If no monograph fits, talk with a regulatory consultant about your options. Your application class also affects the review timeline, so plan for it early. Our guide to NHP Class I, II, and III explains the differences. For more on monographs, see our guide to NNHPD monographs.
What Health Canada Does Not Permit
Health Canada sets clear limits on health product marketing. False or misleading claims to prevent, treat, or cure illnesses are illegal in Canada. Advertisements also must not be false, misleading, or deceptive. In addition, only products authorized for sale can be advertised.
Disease and comparison wording needs extra care. Prescription GLP-1 drugs are authorized to treat type 2 diabetes and obesity. So phrases such as “treats obesity” or “manages type 2 diabetes” describe the authorized uses of those drugs. Wording that says a product “works like” a GLP-1 drug, or “activates GLP-1 pathways,” suggests a drug-like effect. Have a regulatory expert review any wording like this before it appears anywhere.
Finally, avoid any suggestion of official approval. Health Canada never endorses a health product and does not allow its logo in health product advertising.
Marketing Language Outside the Label Also Counts
A common mistake is assuming that Health Canada advertising rules stop at the label. They do not. Health Canada’s guidance on advertising applies to natural health products and to health-related messages on any media, including online and digital platforms. So your website, social posts, and promotional materials all count. For example, if your website mentions GLP-1 and your label does not, that gap needs a review.
Your marketing should stay consistent with your authorized claims across every consumer-facing channel. Digital teams often move faster than regulatory review, so add a review step before you publish.
How the Product Licence Application Process Applies Here
When you submit a product licence application, Health Canada assesses whether your proposed claims are supported by your evidence and aligned with the NHPR. If your application references GLP-1 activity directly, have a regulatory expert review that wording first. Once your NPN is issued, your authorized claims become the reference point for your marketing.
Working with regulatory professionals during pre-submission helps you spot problem wording before you file. Our team supports NHP licensing, including NPN applications and label compliance. For website and social content, our advertising and media compliance service reviews claims and promotional materials for Health Canada and FDA requirements. Reviewing claims early can also reduce back-and-forth.
Key Takeaways
- GLP-1 claims need extra care because prescription GLP-1 drugs are authorized for type 2 diabetes and obesity.
- Your product licence and authorized claims set the boundary for your marketing.
- Comparisons to prescription GLP-1 drugs suggest a drug-like effect, so have them reviewed before you publish.
- Health Canada’s advertising rules apply to websites and social media, not only to labels.
- Reviewing claim language before you file helps you catch problems early.
Frequently Asked Questions
Can I mention GLP-1 anywhere on my NHP product without triggering a drug classification?
It depends on the wording. Health Canada's advertising guidance covers health-related messages on any media, including digital platforms. So your website counts the same as your label. Even an educational mention can shape how readers see your product. One cautious approach is to anchor your copy to your authorized claims. Then have a regulatory expert review any GLP-1 reference before you publish.
Does my NPN mean my GLP-1 marketing is approved?
No. An NPN shows that Health Canada authorized the product for sale. Your advertising must still avoid being false, misleading, or deceptive. Industry is also responsible for meeting the federal advertising requirements. So check every new message against your authorized claims.
Should I use an advertising preclearance agency?
Preclearance is voluntary, but Health Canada strongly recommends it. Independent agencies review consumer-directed advertising for natural health products. You can pair that review with a claims review from your regulatory team. Health Canada lists the agencies on its advertising preclearance page.
Planning Your NHP Claims Before You File
Health Canada’s framework gives brands a clear starting point. Your licence sets your authorized claims, and your marketing needs to stay accurate and consistent with them. GLP-1 wording needs extra care because prescription GLP-1 drugs carry authorized disease uses.If you are planning an NHP with appetite, blood sugar, or metabolic positioning, our team can review your claim approach with you. Learn more about our Canada NHP licensing services, or contact us to talk through your plan before you file.
